Press Releases
AtriCure to Host Analyst & Investor Day on March 26, 2025
March 12, 2025
MASON, Ohio --(BUSINESS WIRE)--Mar. 12, 2025-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today reaffirmed that the company will host an Analyst...
AtriCure Reports Fourth Quarter 2024 and Full Year 2024 Financial Results
February 12, 2025
Fourth Quarter 2024 Worldwide revenue of $124.3 million – an increase of 16.6% year over year Full Year 2024 Worldwide revenue of $465.3 million – an increase of 16.5% year over year Launched cryoSPHERE ® +, cryoSPHERE MAX ™ and AtriClip ® FLEX-Mini ™ devices in the United States , and EnCompass ®...
AtriCure to Announce Fourth Quarter and Full Year 2024 Financial Results
January 22, 2025
MASON, Ohio --(BUSINESS WIRE)--Jan. 22, 2025-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its fourth...
AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2024, Provides Financial Outlook for 2025, and Announces Upcoming Analyst & Investor Day
January 13, 2025
MASON, Ohio --(BUSINESS WIRE)--Jan. 13, 2025-- AtriCure, Inc. (Nasdaq: ATRC) , a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced preliminary financial results for...
AtriCure to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
December 23, 2024
MASON, Ohio --(BUSINESS WIRE)--Dec. 23, 2024-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating...
AtriCure to Participate in the Piper Sandler 36th Annual Healthcare Conference
November 20, 2024
MASON, Ohio --(BUSINESS WIRE)--Nov. 20, 2024-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating...
AtriCure to Participate in the Stifel 2024 Healthcare Conference
November 07, 2024
MASON, Ohio --(BUSINESS WIRE)--Nov. 7, 2024-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating...
AtriCure Reports Third Quarter 2024 Financial Results
October 29, 2024
Worldwide revenue of $115.9 million – an increase of 17.9% year over year U.S. revenue of $95.5 million – an increase of 16.8% year over year Achieved 20% growth on revenues from open appendage management devices in the U.S. International revenue of $20.5 million – an increase of 23.3% year over...
AtriCure to Participate in the UBS Global Healthcare Conference
October 28, 2024
MASON, Ohio --(BUSINESS WIRE)--Oct. 28, 2024-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating...
AtriCure Announces Launch of cryoSPHERE MAX™ Probe for Post-Operative Pain Management
October 15, 2024
MASON, Ohio --(BUSINESS WIRE)--Oct. 15, 2024-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it has launched the cryoSPHERE...